Metsera (NASDAQ:MTSR) Shares Up 4.9% - Still a Buy?

Key Points

• Metsera Inc. shares increased by 4.9% on Wednesday, closing at $34.88 after reaching a high of $34.97.
• Several analysts have issued positive ratings, with Leerink Partners setting an "outperform" rating and a price target of $77.00, and Bank of America increasing their price target from $45.00 to $50.00.
• Institutional investors have shown strong interest, with Alphabet Inc. acquiring a stake worth $135 million during the first quarter.

Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s stock price was up 4.9% during trading on Wednesday . The stock traded as high as $34.97 and last traded at $34.88. Approximately 109,806 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 1,038,420 shares. The stock had previously closed at $33.25.

Analysts Set New Price Targets

MTSR has been the subject of several research reports. Leerink Partners initiated coverage on shares of Metsera in a research report on Tuesday, September 9th. They set an "outperform" rating and a $77.00 price objective for the company. Wall Street Zen raised shares of Metsera from a "sell" rating to a "hold" rating in a research report on Monday. Wells Fargo & Company started coverage on shares of Metsera in a research note on Friday, June 20th. They set an "overweight" rating and a $65.00 target price for the company. Bank of America lifted their price objective on shares of Metsera from $45.00 to $50.00 and gave the stock a "buy" rating in a research note on Thursday, August 28th. Finally, Leerink Partnrs raised shares of Metsera to a "strong-buy" rating in a report on Tuesday, September 9th. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $63.50.

Metsera Stock Performance

The business's 50 day simple moving average is $35.67 and its 200 day simple moving average is $29.01.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Institutional Trading of Metsera

Institutional investors have recently bought and sold shares of the business. Alphabet Inc. acquired a new stake in Metsera during the 1st quarter worth $135,059,000. T. Rowe Price Investment Management Inc. bought a new position in shares of Metsera during the first quarter worth $78,748,000. Invesco Ltd. bought a new position in shares of Metsera during the first quarter worth $271,000. Siren L.L.C. bought a new position in shares of Metsera during the first quarter worth $4,083,000. Finally, Jennison Associates LLC bought a new position in shares of Metsera during the first quarter worth $9,679,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.